Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15999329 | 0.74 | KIF18A (0.36) | SOS1PIN1DYRK1A | |
| SCHEMBL14896890 | 0.68 | HTR3E (0.51) | — | |
| SCHEMBL31696820 | 0.65 | GRIN2D (0.45) | SOS1LRRK2DYRK1A | |
| SCHEMBL24018499 | 0.65 | GRIN2D (0.44) | SOS1DYRK1A | |
| SCHEMBL25272328 | 0.65 | KIF18A (0.38) | LRRK2GRIA1PIN1DYRK1A | |
| SCHEMBL1810998 | 0.65 | GRIN2D (0.45) | SOS1LRRK2DYRK1A | |
| SCHEMBL12983811 | 0.65 | GABRP (0.43) | — | |
| SCHEMBL17306467 | 0.64 | L3MBTL1 (0.42) | — | |
| SCHEMBL15886105 | 0.63 | CHRM4 (0.38) | LRRK2DYRK1A | |
| SCHEMBL10105634 | 0.63 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | CNR1, CNR2, SIGMAR1 | SOS1 638/4885LRRK2 2796/4885GRIA1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.